GILD

SEC source: 0001127602-23-018588 · form4.xml · derivative · entry 3

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,533

Underlying: Common Stock · 2,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-018588 · form4.xml · nonDerivative · entry 2

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,887

SEC source: 0001127602-23-018588 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-018592 · form4.xml · derivative · entry 3

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,041

Underlying: Common Stock · 517 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-018592 · form4.xml · nonDerivative · entry 2

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,576

SEC source: 0001127602-23-018592 · form4.xml · nonDerivative · entry 1

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-014544 · form4.xml · derivative · entry 2

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014544 · form4.xml · nonDerivative · entry 1

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,922

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014548 · form4.xml · derivative · entry 3

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014548 · form4.xml · nonDerivative · entry 2

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,014

SEC source: 0001127602-23-014548 · form4.xml · nonDerivative · entry 1

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,382

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014551 · form4.xml · derivative · entry 2

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014551 · form4.xml · nonDerivative · entry 1

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,392

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014554 · form4.xml · derivative · entry 2

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014554 · form4.xml · nonDerivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 92,653

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

F2 · balance_after: Shares are held in a Revocable Living Trust.

F2 · ownership.nature: Shares are held in a Revocable Living Trust.

SEC source: 0001127602-23-014558 · form4.xml · derivative · entry 2

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014558 · form4.xml · nonDerivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,631

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014562 · form4.xml · derivative · entry 2

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014562 · form4.xml · derivative · entry 1

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,887

Underlying: Common Stock · 1,887 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023.

F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014593 · form4.xml · derivative · entry 2

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014593 · form4.xml · nonDerivative · entry 1

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,230

F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014595 · form4.xml · derivative · entry 2

Kramer Kelly A. · CIK 0001629885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,173

Underlying: Common Stock · 10,173 shares

Expires 2033-05-03

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014595 · form4.xml · derivative · entry 1

Kramer Kelly A. · CIK 0001629885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,284

Underlying: Common Stock · 1,887 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023.

F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023.

SEC source: 0001127602-23-014140 · form4.xml · nonDerivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 90,766

F1 · shares: Upon expiration of a Grantor Retained Annuity Trust, 12,868 shares were transferred to beneficiaries on May 1, 2023.

F2 · ownership.nature: Shares are held in a Revocable Living Trust.

SEC source: 0001127602-23-011726 · form4.xml · derivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,132.3523

Underlying: Common Stock · 28.5799 shares

Expires not disclosed

F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.

F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.

F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

SEC source: 0001127602-23-010126 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,130

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-23-009978 · form4.xml · derivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,605

Underlying: Common Stock · 46,605 shares

Expires 2033-03-10

F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009978 · form4.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,140

Underlying: Common Stock · 10,220 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009980 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,565

Underlying: Common Stock · 74,565 shares

Expires 2033-03-10

F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009980 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,600

Underlying: Common Stock · 16,350 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009980 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,250

Underlying: Common Stock · 7,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009980 · form4.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,644

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-009980 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,188

SEC source: 0001127602-23-009980 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009980 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009982 · form4.xml · derivative · entry 7

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,565

Underlying: Common Stock · 74,565 shares

Expires 2033-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009982 · form4.xml · derivative · entry 6

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,682

Underlying: Common Stock · 16,350 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009982 · form4.xml · derivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,332

Underlying: Common Stock · 7,951 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009982 · form4.xml · derivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,283

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-009982 · form4.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,225

SEC source: 0001127602-23-009982 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009982 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,390

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009984 · form4.xml · derivative · entry 7

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,405

Underlying: Common Stock · 10,405 shares

Expires 2033-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009984 · form4.xml · derivative · entry 6

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,558

Underlying: Common Stock · 6,130 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009984 · form4.xml · derivative · entry 5

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,428

Underlying: Common Stock · 1,320 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009984 · form4.xml · derivative · entry 4

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,748

Underlying: Common Stock · 1,601 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 3

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,212

SEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 2

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 1

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009986 · form4.xml · derivative · entry 7

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2033-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.